M-CSF Induction of Dendritic Cell Subtypes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for effectively inducing dendritic cell formation, particularly plasmacytoid dendritic cells (pDCs), and conventional dendritic cells (cDCs) independently of Fms-like-Tyrosine-Kinase 3-Ligand (FL) and Granulocyte-Macrophage-Colony Stimulating Factor (GM-CSF, which are essential for regulating immune responses and increasing DC numbers in individuals with infections or immunocompromised conditions.
Innovation Solution
An in vitro method involving the culture of hematopoietic precursor cells and administration of Macrophage-Colony Stimulating Factor (M-CSF) to induce pDCs and cDCs, without the need for FL or GM-CSF, using M-CSF to increase pDC numbers by quantifying cell surface markers and cytokine production, and potentially using M-CSF in viral vectors or as nucleic acids for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If GM-CSF is used to induce dendritic cell development, then dendritic cell numbers increase, but the method cannot independently induce plasmacytoid dendritic cells and requires FL or GM-CSF co-administration
Solution Approach 1:
The invention extracts and isolates the specific function of M-CSF to induce pDCs and cDCs independently, separating this function from the requirement of FL or GM-CSF co-administration. By identifying that M-CSF alone can drive DC development from hematopoietic precursors, the patent removes the dependency on other growth factors, thereby achieving independent induction while maintaining high DC yields.
Solution Approach 2:
The invention changes the parameter of growth factor composition by using M-CSF at specific concentrations (e.g., 10-100 ng/mL) in defined culture conditions, replacing the traditional FL+GM-CSF combination. This parameter change enables independent DC induction while optimizing cell yield and differentiation efficiency through controlled M-CSF dosing regimens.
2Adaptability or versatility
If M-CSF is used to induce dendritic cell development independently of FL and GM-CSF, then independence is achieved, but the effectiveness and efficiency of DC induction must be validated
Solution Approach 1:
The invention incorporates feedback mechanisms to validate M-CSF effectiveness by monitoring DC differentiation markers (e.g., CD11c, CD80, CD86 expression), cell surface phenotype changes, and functional assays (antigen presentation, cytokine production). This feedback system ensures that independent M-CSF induction achieves reliable DC generation with proper maturation and immunological functionality.
Solution Approach 2:
The invention performs preliminary validation by establishing optimal M-CSF concentration ranges, culture durations, and precursor cell selection criteria before full-scale DC induction. Pre-experiments determine the minimum effective M-CSF dose and optimal culture conditions, ensuring reliable and reproducible DC generation from hematopoietic precursors under defined conditions.
3Quantity of substance
If traditional DC induction methods using FL and GM-CSF are used, then DC development is established, but the process requires multiple growth factors and complex culture conditions
Solution Approach 1:
The invention extracts the essential function of growth factor combinations by identifying M-CSF as the single critical factor for DC induction. By removing FL and GM-CSF from the culture system and relying solely on M-CSF, the patent simplifies culture conditions while maintaining effective DC yield, reducing the number of reagents, handling steps, and monitoring parameters required.
Solution Approach 2:
The invention demonstrates that M-CSF alone can perform multiple functions traditionally requiring separate growth factors: inducing DC differentiation, supporting cell survival, and promoting maturation. This multi-functionality of M-CSF eliminates the need for complex growth factor cocktails, simplifying the overall culture system while achieving comprehensive DC development.
Data Source
Figure 1A~1C
Figure 2
Figure 3A~3D
AI summary
A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor (M-CSF) is provided. M-CSF induces DCs to differentiate into Subtypes, for example plasmacytoid DCs and conventional DCs. Said differentiation is independent of Fms-like-Tyrosine- Kinase 3-Ligand (FL) and/or Granulocyte-Macrophage-Colony Stimulating Factor (GM-CSF). Induction with M-CSF can be achieved in vitro from hematopoietic precursors, such as bone marrow cells, or in vivo. In vitro, M-CSF-derived DCs can be used to produce cytokines and to stimulate other immune response cells. M-CSF can also be used to induce precursor cells removed from an animal to develop into DCs. In addition, these isolated DCs can be exposed to antigens to stimulate a specific immune response when reintroduced into the animal. Treatments for Cancers, such as Acute Myeloid Leukemia, and autoimmune diseases such as Systemic Lupus Erythematosus, are also provided in the invention.